Vivimed Labs reports Q2 losses, files for pre-packaged insolvency, expects trading suspension revocation
Vivimed Labs reported Q2 losses, approved filing for pre-packaged insolvency, and expects trading suspension revocation. Auditors issued a qualified opinion due to unprovided interest expenses.
The decision to file for a pre-packaged insolvency resolution process is a major corporate action with high impact on the company's future, shareholders, and creditors. The recurring qualified audit opinion further highlights material financial concerns and potential restructuring.
The company reported significant losses for the quarter, is initiating a pre-packaged insolvency resolution process due to financial stress, and received a qualified audit opinion for not booking substantial interest expenses, all indicating severe financial distress.
* The Board of Directors of Vivimed Labs Limited, at its meeting on November 13, 2025, approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. * Standalone Financial Highlights (Quarter ended September 30, 2025): * Revenue from Operations: ₹186.59 million (₹18.66 crore) * Total Revenue: ₹188.19 million (₹18.82 crore) * Profit for the period: ₹(74.45) million (₹(7.45) crore) loss * Consolidated Financial Highlights (Quarter ended September 30, 2025): * Revenue from Operations: ₹206.12 million (₹20.61 crore) * Total Revenue: ₹208.25 million (₹20.83 crore) * Profit for the period: ₹(73.01) million (₹(7.30) crore) loss * The Board approved the filing of an application under Section 54A and other applicable provisions read with Section 10 of the Insolvency and Bankruptcy Code (IBC) to the National Company Law Tribunal (NCLT) for a pre-packaged insolvency resolution process. This is subject to approval from shareholders by way of a Special Resolution. * A draft EGM Notice was approved to seek shareholder consent for this NCLT application through remote e-voting. * The company expects the revocation of the suspension in trading of its equity shares from stock exchanges in a few days, having submitted all relevant documents and paid applicable fees. * The statutory auditors issued a qualified opinion on both standalone and consolidated financial results. The qualification stems from the company not providing for interest expenses of ₹157.28 million (₹15.73 crore) for the quarter ended September 30, 2025 (₹307.11 million or ₹30.71 crore for the half-year) on an accrual basis for loans. This omission understates liabilities and losses. * Management's View on Audit Qualification: The company is engaged in negotiations with its bankers for a settlement and is confident of reaching a resolution, hence the interest on outstanding loans was not recorded for the quarter ended September 30, 2025.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.